Arthritis psoriatica: vizsgálatok itt: Lengyelország
13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 4. fázisTaking peopleAn open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
- Where
- Bydgoszcz, Cracow, Lublin, Torun, Warsaw
- People
- 339 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00 - 2. fázisTaking peopleStudy of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
- Where
- Bialystok, Bydgoszcz, Elblag, Pruszków, Warsaw
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- AbbVie
See details and how to joinNCT06865105 - 1. fázisTaking peopleA Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
- Where
- Bialystok, Bydgoszcz, Bytom, Elblag, Krakow, Lodz, Lublin, Nowa Sól, Olsztyn, Płońsk, Poznan, Torun, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 392 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07290036 - 3. fázisTaking peopleA Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
- Where
- Krakow, Lodz, Warsaw
- Életkor
- 1 év to 18 év
- People
- 190 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT03773965 - 3. fázisTaking peopleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Where
- Rzeszów, Sosnowiec, Warsaw
- Életkor
- 3 év to 64 év
- People
- 196 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00 - 3. fázisTaking peopleAn Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
- Where
- Cracow, Sosnowiec
- Életkor
- 2 év to 18 év
- People
- 40 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06668181 · EU 2023-508845-41-00 - 3. fázisTaking peopleApremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
- Where
- Cracow, Lodz, Warsaw
- Életkor
- 5 év to 17 év
- People
- 60 worldwide
- Run by
- Amgen
See details and how to joinNCT04804553 · EU 2023-503435-17-00 - 3. fázisTaking peopleA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- Where
- Bialystok, Białystok, Bytom, Cracow, Dąbrówka, Elblag, Katowice, Lodz, Nowa Sol, Olsztyn, Opole, Poznan, Sochaczew, Torun, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 1088 worldwide
- Run by
- Takeda
See details and how to joinNCT06671483 · EU 2024-513111-27-00 - 3. fázisTaking peopleContinuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- Where
- Białystok, Bydgoszcz, Bytom, Cracow, Częstochowa, Dąbrówka, Elblag, Gdynia, Katowice, Lodz, Lublin, Nowa Sol, Olsztyn, Opole, Poznan, Sochaczew, Torun, Warsaw, Wroclaw, Wrocław
- Életkor
- 18 év and over
- People
- 1182 worldwide
- Run by
- Takeda
See details and how to joinNCT07286058 · EU 2025-522586-30-00 - 3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
- Where
- Cracow, Lodz, Lublin, Sosnowiec, Warsaw
- Életkor
- 5 év to 17 év
- People
- 40 worldwide
- Run by
- AbbVie
See details and how to joinNCT06100744 · EU 2023-506026-36-00 - 4. fázisTaking peopleA Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
- Where
- Bydgoszcz, Bytom, Elblag, Krakow, Kraków, Lublin, Poznan, Warsaw, Warszawa, Wroclaw
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- CARE ARTHRITIS LTD.
See details and how to joinNCT06454188 · EU 2023-510242-24-00 - 3. fázisNot yet taking people in LengyelországA study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
- Where
- Bialystok, Bydgoszcz, Bytom, Cracow, Częstochowa, Dąbrówka, Debica, Elblag, Gdynia, Katowice, Lodz, Lublin, Nadarzyn, Nowa Sol, Olsztyn, Poznan, Siedlce, Sochaczew, Swidnica, Torun, Warsaw, Warszawa, Wołomin, Wroclaw, Zamość
- Életkor
- 18 év and over
- People
- 948 worldwide
- Run by
- MoonLake Immunotherapeutics AG
See details and how to join2025-522471-28-00 · EU 2025-522471-28-00 - No phaseTaking peopleAn Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
- Where
- Poznan, Wroclaw
- Életkor
- 18 év to 75 év
- People
- 1200 worldwide
- Run by
- AbbVie
See details and how to joinNCT06764693